Novartis stock holds as investors await fresh numbers

Novartis stock continues to trade against a backdrop shaped by the company’s latest annual and quarterly disclosures, with the Swiss group reporting USD 50.32 billion in net sales for 2025 and USD 11.94 billion in core operating income, while 2026 guidance calls for mid-single-digit sales growth and a core operating income margin around the mid-30s.

2025 set the base

For the full year 2025, Novartis reported net sales of USD 50.32 billion, up from the prior year, and core operating income of USD 11.94 billion, which it said reflected a 23% increase in constant currencies. The same reporting cycle also showed core diluted earnings per share of USD 8.01 for 2025, giving the market a clean earnings base for comparison.

The quarterly cadence matters as well. In the fourth quarter of 2025, Novartis posted net sales of USD 13.2 billion and core operating income of USD 4.2 billion, numbers that frame how investors read the 2026 run rate and the share-price reaction into the next update.

Margin still drives valuation

Novartis has guided for mid-single-digit sales growth in 2026 and a core operating income margin of around the mid-30s. That combination matters because the group’s 2025 core margin already sat near the mid-20s on the reported figures, so the market focus is on whether the business can extend operating leverage without depending on a single product cycle.

The comparison is direct: USD 11.94 billion of core operating income on USD 50.32 billion of sales in 2025 implies a margin of roughly 23.7%, leaving room for expansion if the 2026 guidance is met. For investors, that gap between the reported base and the guided margin is the number that matters most.

Cosentyx remains important

Within the portfolio, Cosentyx remains one of the company’s most important product lines, and its sales trend still helps explain the broader revenue mix. Novartis said the product family contributed to the 2025 base that supported the full-year sales figure of USD 50.32 billion, alongside the performance of other major therapies.

The wider product picture matters because Novartis is no longer valued only on one blockbuster. The group’s reported 2025 core diluted EPS of USD 8.01 and its margin guidance for 2026 show why the product mix now matters as much as headline growth.

Market value anchors the story

The share price reference line is best read together with the operating figures above: the latest guidance implies a business still in expansion mode, but the stock’s longer-term re-rating depends on whether the 2026 margin target is credible against the 2025 base. That is why the reported numbers from 2025 and the 2026 guidance remain the key frame for Novartis stock.

Novartis is listed on the SIX Swiss Exchange, and the company remains a large-cap pharmaceutical name in the Swiss market. The article’s price line is omitted because no dated market quote is available in the provided research set; the reporting figures above are the best current anchor for the stock narrative.

Product mix and dosing

Cosentyx is a representative product for the group because it sits in a major immunology franchise and helps illustrate how Novartis balances growth across multiple therapies. The company’s 2025 sales base of USD 50.32 billion shows the scale behind that mix, while the 2026 guidance points to continued emphasis on earnings quality rather than volume alone.

Closing frame

Novartis stock is therefore being read through a simple lens: USD 50.32 billion in 2025 sales, USD 11.94 billion in core operating income, and a 2026 margin target in the mid-30s. Those three figures define the current investment debate more clearly than any short-term headline move.